We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01718938
First Posted: November 1, 2012
Last Update Posted: May 13, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Alfa Wassermann S.p.A.
Information provided by (Responsible Party):
Theravance Biopharma R & D, Inc.
  Purpose

This is a multicenter, randomized, double-blind, incomplete block, three period fixed sequence crossover, multicenter, placebo-controlled study. The study will assess three oral doses of velusetrag (5 mg, 15 mg, and/or 30 mg) or placebo, administered once daily in three periods of 1-week duration each, with a 1-week washout period between treatment periods, in subjects with diabetic or idiopathic gastroparesis.

Study 0093 will evaluate the effect of velusetrag in subjects with diabetic or idiopathic gastroparesis by assessing changes in gastric emptying.


Condition Intervention Phase
Gastroparesis Drug: velusetrag dose 1 Drug: velusetrag dose 2 Drug: velusetrag dose 3 Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase 2 Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis

Further study details as provided by Theravance Biopharma R & D, Inc.:

Primary Outcome Measures:
  • Gastric emptying half time (GE t1/2) [ Time Frame: From baseline to week 5 ]

Secondary Outcome Measures:
  • Duration of lag time to gastric emptying (tlag) [ Time Frame: From baseline to Week 5 ]
  • Vital signs [ Time Frame: From baseline to Day 49 ]
    Assess the safety and tolerability in subjects with diabetic or idiopathic gastroparesis

  • ECGs [ Time Frame: From baseline to Day 49 ]
  • Number of adverse events [ Time Frame: From baseline to Day 49 ]
Enrollment: 34
Study Start Date: December 2012
Study Completion Date: February 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sequence 1
3-way crossover of velusetrag or placebo
 Drug: velusetrag dose 1
Other Name: TD-5108
Drug: velusetrag dose 2
Other Name: TD-5108
Drug: velusetrag dose 3
Other Name: TD-5108
Drug: placebo
Experimental: Sequence 2
3-way crossover of velusetrag or placebo
 Drug: velusetrag dose 1
Other Name: TD-5108
Drug: velusetrag dose 2
Other Name: TD-5108
Drug: velusetrag dose 3
Other Name: TD-5108
Drug: placebo
Experimental: Sequence 3
3-way crossover of velusetrag or placebo
 Drug: velusetrag dose 1
Other Name: TD-5108
Drug: velusetrag dose 2
Other Name: TD-5108
Drug: velusetrag dose 3
Other Name: TD-5108
Drug: placebo
Experimental: Sequence 4
3-way crossover of velusetrag or placebo
 Drug: velusetrag dose 1
Other Name: TD-5108
Drug: velusetrag dose 2
Other Name: TD-5108
Drug: velusetrag dose 3
Other Name: TD-5108
Drug: placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Symptoms of gastroparesis (e.g., nausea, early satiety, fullness, bloating, upper abdominal pain, retching or vomiting) for at least 3 months prior to Screening
  • Body Mass Index (BMI) between 18 and 35 kg/m2, inclusive
  • Gastroparesis Cardinal Symptom Index (GCSI-2W) composite score ≥2 and ≤4 at Screening
  • Delayed gastric emptying, defined as a gastric emptying half-time (GE t1/2) > 160 minutes as determined by [13C]-octanoate breath test, at Screening
  • Upper gastrointestinal (UGI) obstruction ruled out by endoscopy or other imaging reasonably proximal to the diagnosis of gastroparesis

Exclusion Criteria:

  • Acute severe gastroenteritis within 2 weeks prior to Screening
  • History of gastric outlet obstruction
  • Prior history of gastric surgery, including but not limited to gastrectomy, gastric bypass, gastric banding, pyloroplasty, vagotomy, or fundoplication
  • Recurrent vomiting, defined as vomiting more than 2 days per week
  • Hospitalization for treatment of gastroparesis or complications of diabetes within 4 weeks prior to Screening
  • Presence of thyroid dysfunction not controlled by treatment. Subjects with abnormal thyroid stimulating hormone (TSH), hypothyroidism, or hyperthyroidism at Screening
  • If Type 1 or Type 2 diabetic, a glycosylated hemoglobin (HbA1c) level >10% or a glucose > 250 mg/dL at Screening
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01718938


Locations
United States, Arizona
Desert Sun Clinical Research
Tucson, Arizona, United States, 85710
United States, California
Axis Clinical Trials
Los Angeles, California, United States, 90036
Ventura Clinical Trials
Ventura, California, United States, 93003
United States, Indiana
Indiana University Hospital
Indianapolis, Indiana, United States, 46202
United States, Mississippi
GI Associates & Endoscopy Center
Jackson, Mississippi, United States, 39202
United States, Missouri
Center for Digestive and Liver Diseases, Inc.
Mexico, Missouri, United States, 65265
United States, North Carolina
Wake Research Associates, LLC
Raleigh, North Carolina, United States, 27612
United States, Oregon
Northwest Gastroenterology Clinic
Portland, Oregon, United States, 97210
United States, Virginia
Digestive and Liver Disease Specialists
Norfolk, Virginia, United States, 23502
Sponsors and Collaborators
Theravance Biopharma R & D, Inc.
Alfa Wassermann S.p.A.
  More Information

Responsible Party: Theravance Biopharma R & D, Inc.
ClinicalTrials.gov Identifier: NCT01718938     History of Changes
Other Study ID Numbers: 0093
First Submitted: October 29, 2012
First Posted: November 1, 2012
Last Update Posted: May 13, 2015
Last Verified: May 2015

Keywords provided by Theravance Biopharma R & D, Inc.:
Gastroparesis
Diabetic
Idiopathic
Delayed gastric emptying

Additional relevant MeSH terms:
Gastroparesis
Stomach Diseases
Gastrointestinal Diseases
Digestive System Diseases
 Paralysis
Neurologic Manifestations
Signs and Symptoms


To Top